Greater Suppression of Glucagon, Lipolysis, and Ketogenesis with Insulin Glargine U300 as Compared with Glargine U100 in Type 1 Diabetes Mellitus.
Glargine U300
Glucagon
Ketogenesis
Lipolysis
Type 1 diabetes
Journal
Diabetes technology & therapeutics
ISSN: 1557-8593
Titre abrégé: Diabetes Technol Ther
Pays: United States
ID NLM: 100889084
Informations de publication
Date de publication:
01 2020
01 2020
Historique:
pubmed:
15
8
2019
medline:
6
11
2020
entrez:
15
8
2019
Statut:
ppublish
Résumé
The aim of this study was to establish the effects of clinical doses of Gla-300 versus Gla-100 on suppression of glucagon, lipolysis, and ketogenesis in type 1 diabetes mellitus (T1DM). Eighteen persons with T1DM (age 40 ± 12 years, diabetes duration 26 ± 12 years, body mass index 23.4 ± 2 kg/m
Identifiants
pubmed: 31411498
doi: 10.1089/dia.2019.0231
doi:
Substances chimiques
Hypoglycemic Agents
0
Insulin Glargine
2ZM8CX04RZ
Glucagon
9007-92-5
Types de publication
Comparative Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM